X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
jnj-42756493 (8) 8
index medicus (4) 4
chemistry, medicinal (3) 3
fibroblast growth factor receptors (3) 3
pharmacology & pharmacy (3) 3
urothelial carcinoma (3) 3
chemotherapy (2) 2
covalent inhibitors (2) 2
drug dosages (2) 2
egfr (2) 2
erdafitinib (2) 2
fibroblast growth factor (2) 2
immunotherapy (2) 2
inhibitor (2) 2
kinases (2) 2
medicine & public health (2) 2
metastases (2) 2
metastasis (2) 2
oncology (2) 2
pharmacology/toxicology (2) 2
research & development--r&d (2) 2
tumors (2) 2
abridged index medicus (1) 1
activation (1) 1
analysis (1) 1
antitumor activity (1) 1
azd4547 (1) 1
biochemistry & molecular biology (1) 1
bladder cancer (1) 1
bladder cancer therapy genitourinary (1) 1
cancer patients (1) 1
cancer research (1) 1
cancer therapies (1) 1
cancer therapy (1) 1
care and treatment (1) 1
cell adhesion & migration (1) 1
cell growth (1) 1
cell lung-cancer (1) 1
ch5183284/debio 1347 (1) 1
cholangiocarcinoma (1) 1
collaboration (1) 1
comprehensive molecular characterization (1) 1
concentration-qtc modeling (1) 1
concentration–qtc modeling (1) 1
conduction (1) 1
confidence intervals (1) 1
creatinine (1) 1
data analysis (1) 1
depolarization (1) 1
derivatives (1) 1
design (1) 1
diagnosis (1) 1
discovery (1) 1
diurnal-variation (1) 1
dose-escalation (1) 1
ecg analysis (1) 1
editorials (1) 1
efficacy (1) 1
ekg (1) 1
electrocardiogram (1) 1
electrocardiography (1) 1
esophagus (1) 1
evaluate (1) 1
expression (1) 1
fda approval (1) 1
fgf19 (1) 1
fgfr3 (1) 1
fibroblast growth factor receptor 1 (1) 1
fibroblast growth factor receptor 2 (1) 1
fibroblast-growth-factor-19 (1) 1
fibroblasts (1) 1
full text (1) 1
gene amplification (1) 1
gene expression (1) 1
growth factors (1) 1
growth-factor receptor (1) 1
health aspects (1) 1
heart beat (1) 1
heart rate (1) 1
hepatocytes (1) 1
holter data (1) 1
immune clearance (1) 1
immunology (1) 1
insights (1) 1
internal medicine (1) 1
interval (1) 1
liver cancer (1) 1
lung cancer (1) 1
lymphoma (1) 1
lymphomas (1) 1
medical research (1) 1
medicine, general & internal (1) 1
microenvironment (1) 1
multicenter (1) 1
mutation (1) 1
mutational landscape (1) 1
non-small cell lung carcinoma (1) 1
outliers (1) 1
overcome resistance (1) 1
pan-fgfr inhibitors (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Medicinal Chemistry, ISSN 0022-2623, 03/2019, Volume 62, Issue 6, pp. 2905 - 2915
Hepatocellular carcinoma (HCC) is a lethal disease with limited therapeutic options and a particularly poor prognosis. Aberrant fibroblast growth factor 19... 
DOSE-ESCALATION | PONATINIB | CHEMISTRY, MEDICINAL | COVALENT INHIBITORS | FGF19 | JNJ-42756493 | PHASE-I | FIBROBLAST-GROWTH-FACTOR-19 | EXPRESSION | DISCOVERY | INSIGHTS
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 10/2018, Volume 61, Issue 20, pp. 9085 - 9104
Fibroblast growth factor receptors (FGFR1–4) are promising therapeutic targets in many cancers. With the resurgence of interest in irreversible inhibitors,... 
CH5183284/DEBIO 1347 | AZD4547 | SELECTIVE INHIBITOR | DESIGN | CHEMISTRY, MEDICINAL | COVALENT INHIBITORS | JNJ-42756493 | OVERCOME RESISTANCE | DERIVATIVES | EGFR | STRATEGIES
Journal Article
CANCER IMMUNOLOGY RESEARCH, ISSN 2326-6066, 09/2019, Volume 7, Issue 9, pp. 1457 - 1471
The success of targeted or immune therapies is often hampered by the emergence of resistance and/or clinical benefit in only a subset of patients. We... 
CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | RESPONSES | MICROENVIRONMENT | ONCOLOGY | IMMUNOTHERAPY | JNJ-42756493 | MUTATIONAL LANDSCAPE | RESISTANCE | SENSITIVITY | IMMUNOLOGY | EGFR
Journal Article
DRUGS OF TODAY, ISSN 1699-3993, 08/2019, Volume 55, Issue 8, pp. 495 - 501
Erdafitinib is the first Food and Drug Administration (FDA)-approved oral pan-fibroblast growth factor receptor (FGFR) kinase inhibitor that binds to four... 
ACTIVATION | Bladder cancer therapy Genitourinary | JNJ-42756493 | Erdafitinib | Pan-FGFR inhibitors | Treatment of solid tumors | CHEMOTHERAPY | TRIAL | cancer therapy | PHARMACOLOGY & PHARMACY | Urothelial carcinoma | INHIBITOR | FGFR3
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.